Related references
Note: Only part of the references are listed.KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
N. Nakayama et al.
BRITISH JOURNAL OF CANCER (2008)
The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer
M. J. Palayekar et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
KRAS and BRAF mutations in ovarian tumors:: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants
Doris Mayr et al.
GYNECOLOGIC ONCOLOGY (2006)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biochip for K-ras mutation screening in ovarian cancer
G Fabjani et al.
CLINICAL CHEMISTRY (2005)
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours
NLG Sieben et al.
JOURNAL OF PATHOLOGY (2004)
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors
CL Ho et al.
CANCER RESEARCH (2004)
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
ML Gemignani et al.
GYNECOLOGIC ONCOLOGY (2003)
Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes
M Fujita et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy
J Diebold et al.
LABORATORY INVESTIGATION (2003)
Genetic alterations in endometrial hyperplasia and cancer
G Fabjani et al.
CANCER LETTERS (2002)
Share Paper
